Company news

EyePoint, Inc. news in 2022

EyePoint, Inc.'s news releases, calls and decks from 2022, newest first.

View company

EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments

November 1, 2022

EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022

October 25, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy

September 28, 2022

EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments

August 2, 2022

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD

July 31, 2022

EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

July 26, 2022

EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update

July 17, 2022

EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

July 14, 2022

EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022

July 10, 2022

EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors

July 10, 2022

EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors

June 22, 2022

EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

June 20, 2022

EyePoint Pharmaceuticals to Present 12-Month Results from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD at the American Society of Retina Specialists 2022 Annual Meeting

June 9, 2022

EyePoint Pharmaceuticals to Present at the H.C Wainwright Global Healthcare Investment Conference

May 16, 2022

EyePoint Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Developments

May 3, 2022

EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

May 3, 2022

EyePoint Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022

April 26, 2022

EyePoint Pharmaceuticals to Participate in Fireside Chat at the B. Riley 2022 Virtual Neuro & Ophthalmology Conference

April 20, 2022

EyePoint Pharmaceuticals Announces Debt Refinancing with $45M Credit Facilities from Silicon Valley Bank

March 8, 2022

EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officer

March 6, 2022

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Developments

March 2, 2022

EyePoint Pharmaceuticals to Participate in Fireside Chat at the Cowen 42nd Annual Health Care Conference

February 28, 2022

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

February 23, 2022

EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD

February 11, 2022

EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

January 9, 2022

EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements

January 9, 2022

Calls in 2022

Decks in 2022